CARVYKTI®▼ (ciltacabtagene autoleucel; cilta-cel) is the first BCMA-targeted treatment approved by the European Commission for patients with relapsed : vimarsana.com

CARVYKTI®▼ (ciltacabtagene autoleucel; cilta-cel) is the first BCMA-targeted treatment approved by the European Commission for patients with relapsed and refractory multiple myeloma who have received at least one prior line of therapy Expanded indication for this one-time infusion may provide pati...

Related Keywords

Spain , Beerse , Region Flamande , Belgium , Edmond Chan , Drug Administration , European Union , Committee For Orphan Medicinal Products , Janssen Cilag International , European Medicines Agency , European Commission , Johnson , Area Lead Haematology , Johnson Innovative , New England Journal , Professor Jes , San Miguel , Translational Medicine , Universidad De Navarra , Jordan Schecter , Vice President , Disease Area Leader , Multiple Myeloma , Orphan Medicinal Products , Product Characteristics , Innovative Medicine ,